Deutsche Bank downgraded Argenx (ARGX) to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Phase 3 Study on Efgartigimod: A Potential Game-Changer in Autoimmune Treatment
- Argenx Advances in Systemic Sclerosis Treatment with Efgartigimod PH20 SC Study
- Argenx’s Phase 3 Study on Empasiprubart: A Potential Game-Changer for MMN Treatment?
- Argenx’s CIDP Study: Transitioning from IVIg to Efgartigimod PH20 SC
- Argenx Advances Pediatric gMG Treatment with Efgartigimod Study